DE60327655D1 - Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie - Google Patents

Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie

Info

Publication number
DE60327655D1
DE60327655D1 DE60327655T DE60327655T DE60327655D1 DE 60327655 D1 DE60327655 D1 DE 60327655D1 DE 60327655 T DE60327655 T DE 60327655T DE 60327655 T DE60327655 T DE 60327655T DE 60327655 D1 DE60327655 D1 DE 60327655D1
Authority
DE
Germany
Prior art keywords
induced
taxol
neuropathy
treating
sensoric neuropathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60327655T
Other languages
English (en)
Inventor
David L Shelton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rinat Neuroscience Corp
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Application granted granted Critical
Publication of DE60327655D1 publication Critical patent/DE60327655D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
DE60327655T 2002-12-23 2003-12-23 Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie Expired - Lifetime DE60327655D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43614702P 2002-12-23 2002-12-23
PCT/US2003/041367 WO2004058190A2 (en) 2002-12-23 2003-12-23 Methods for treating taxol-induced sensory neuropathy

Publications (1)

Publication Number Publication Date
DE60327655D1 true DE60327655D1 (de) 2009-06-25

Family

ID=32682348

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60327655T Expired - Lifetime DE60327655D1 (de) 2002-12-23 2003-12-23 Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie

Country Status (10)

Country Link
US (1) US20050089521A1 (de)
EP (1) EP1581759B1 (de)
JP (1) JP2006513187A (de)
AT (1) ATE431157T1 (de)
AU (1) AU2003300397A1 (de)
CA (1) CA2511295A1 (de)
DE (1) DE60327655D1 (de)
ES (1) ES2326080T3 (de)
NZ (1) NZ540879A (de)
WO (1) WO2004058190A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084836A2 (en) * 2003-03-20 2004-10-07 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
SG166768A1 (en) * 2003-12-23 2010-12-29 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) * 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) * 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
EP1400536A1 (de) * 1991-06-14 2004-03-24 Genentech Inc. Verfahren zur Herstellung humanisierter Antikörper
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0730646A1 (de) * 1993-11-23 1996-09-11 Genentech, Inc. Rse, protein tyrosin kinasen
AU698975B2 (en) * 1993-11-23 1998-11-12 Genentech Inc. Kinase receptor activation assay
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6436908B1 (en) * 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
UA65542C2 (uk) * 1996-06-25 2004-04-15 Сефалон, Інк. Спосіб пригнічення надлишкового продукування фактора некрозу пухлин альфа , спосіб полегшення шкідливих ефектів надлишкового продукування фактора некрозу пухлин альфа та спосіб лікування запального стану або захворювання, пов'язаного з фактором некрозу пухлин.
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
KR100823764B1 (ko) * 2000-06-22 2008-04-21 제넨테크, 인크. 아고니스트 안티-티알케이-씨 모노클로날 항체
AU2001286930A1 (en) * 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
WO2004084836A2 (en) * 2003-03-20 2004-10-07 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos

Also Published As

Publication number Publication date
WO2004058190A3 (en) 2005-03-10
AU2003300397A1 (en) 2004-07-22
JP2006513187A (ja) 2006-04-20
EP1581759A4 (de) 2006-08-02
WO2004058190A2 (en) 2004-07-15
NZ540879A (en) 2008-08-29
EP1581759B1 (de) 2009-05-13
ES2326080T3 (es) 2009-09-30
US20050089521A1 (en) 2005-04-28
ATE431157T1 (de) 2009-05-15
CA2511295A1 (en) 2004-07-15
EP1581759A2 (de) 2005-10-05

Similar Documents

Publication Publication Date Title
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
DE60102016D1 (de) Verfahren zur behandlung von beweggungsstörungen
DE602006019753D1 (de) Verfahren und gerät zur behandlung von aneurysmen der a. thoracica
DE60122532D1 (de) Verfahren zur behandlung von mehreren bohrlochintervallen
DE60335921D1 (de) Thrombusdetektor, vorrichtung zur behandlung von thromben und verfahren dafür
DE60120520D1 (de) Verfahren zur behandlung von abwasser
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
ATE395083T1 (de) Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
DE602004010381D1 (de) Verfahren und vorrichtung zur behandlung von wasser für eine einpressbohrung
ATE435026T1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE411018T1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
DE60310400D1 (de) Botulinustoxine zur behandlung von priapismus
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
DE50104023D1 (de) Verfahren zum auffinden von verbindungen, welche zur behandlung und/oder prophylaxe von obesitas geeignet sind
ATE470453T1 (de) Verfahren zur behandlung von atherosklerose
DE602004004883D1 (de) Vegf-antagonisten zur behandlung von diabetes
DE60219658D1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
DE60327655D1 (de) Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie
DE60308045D1 (de) Pflanzenextrakte aus argyrolobium roseum zur behandlung von diabetes
DE50213931D1 (de) Verfahren und vorrichtung zur behandlung von fehlerverdacht
DE602004010548D1 (de) Verfahren zur behandlung von tierhäuten
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE60229123D1 (de) Behandlung von fibromyalgie mit pindolol
ATA20122001A (de) Verfahren zur behandlung von cellulosischen formkörpern

Legal Events

Date Code Title Description
8364 No opposition during term of opposition